tadalafiil - نتائج البحث

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

لاتفيا - اللاتفية - Zāļu valsts aģentūra

lopinavir/ritonavir ranbaxy 100 mg/25 mg apvalkotās tabletes

ranbaxy uk ltd., united kingdom - lopinavirum, ritonavirum - apvalkotās tabletes - 100 mg/25 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

lopinavir/ritonavir sun 200 mg/50 mg apvalkotās tabletes

sun pharmaceutical industries europe b.v., netherlands - lopinavirum, ritonavirum - apvalkotā tablete - 200 mg/50 mg

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hipertensija, plaušu slimība - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektivitāte ir redzams pao iedzīvotājiem, tostarp aetiologies, idiopātiska vai iedzimtības pao, vai arī pao, kas saistīta ar saistaudu slimības. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.